vertex pharmaceuticals vrtx

Vertex Pharma Stock Surges

Vertex (VRTX) Secures FDA Approval for Highly-Awaited Non-Opioid Painkiller

U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its long-awaited non-opioid

Seeking Alpha · 9h

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

The Wall Street Journal on MSN · 1d

Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug

Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.

England, Vertex Pharmaceuticals and Sickle Cell Disease

Seeking Alpha · 16h

Vertex wins reimbursement deal for CRISPR-partnered sickle cell therapy in England

Vertex Pharmaceuticals (VRTX) stock gains as England opts to reimburse its CRSPR (CRSP)-partnered gene therapy Casgevy to treat sickle cell disease. Read more here.

Business Insider · 19h

Vertex In CASGEVY Reimbursement Deal With NHS England For Sickle Cell Disease Patients

Vertex Pharmaceuticals Inc. (VRTX), a commercial-stage global biotechnology company, announced Friday a reimbursement agreement with

The Bakersfield Californian · 19h

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ® (exagamglogene autotemcel).

11h

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

14h

Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...

2hon MSN

Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges

Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...

11h

Vertex Pharmaceuticals Shares Are Up Today: What's Going On?

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

Vertex Pharmaceuticals (NASDAQ:VRTX) lifts 3.2% this week, taking five-year gains to 83%

The simplest way to invest in stocks is to buy exchange traded funds. But you can do a lot better than that by ...

1don MSN

Jim Cramer on Vertex Pharmaceuticals Incorporated (VRTX)’s Suzetrigine: ‘I Don’t See A Lot Of Upside Because That Was The Drug Of The Future For Vertex’

We recently compiled a list of the Jim Cramer Shed Light on These 9 Stocks. In this article, we are going to take a look at ...

AFP20h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

Zacks.com on MSN3d

Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $440.68, marking a -0.72% move from the previous day.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results